We are live on ! Find out more
ANIX icon

Anixa Biosciences

71 hedge funds and large institutions have $17.8M invested in Anixa Biosciences in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

526% more call options, than puts

Call options by funds: $144K | Put options by funds: $23K

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

46% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 13

8% more funds holding

Funds holding: 6671 (+5)

0.85% more ownership

Funds ownership: 16.45%17.3% (+0.85%)

1% less capital invested

Capital invested by funds: $17.9M → $17.8M (-$113K)

Holders
71
Holders Change
+5
Holders Change %
+7.58%
% of All Funds
0.86%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
19
Reduced
13
Closed
8
Calls
$144K
Puts
$23K
Net Calls
+$121K
Net Calls Change
+$53K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.55M +$152K +37,232 +3%
LNWTC
2
Laird Norton Wetherby Trust Company
Washington
$1.83M -$37.7K -9,208 -2%
DADC
3
D.A. Davidson & Co
Montana
$1.68M -$307K -75,000 -12%
UBS Group
4
UBS Group
Switzerland
$1.43M -$63.1K -15,407 -3%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.1M +$29.8K +7,271 +2%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$786K +$703K +171,687 +214%
MWM
7
Mission Wealth Management
California
$646K -$611K -149,252 -42%
BlackRock
8
BlackRock
New York
$512K +$12.1K +2,961 +2%
State Street
9
State Street
Massachusetts
$496K +$158K +38,540 +32%
6CM
10
683 Capital Management
New York
$355K +$465K +113,636 New
ECM
11
ExodusPoint Capital Management
New York
$293K +$385K +93,931 New
LPL Financial
12
LPL Financial
California
$280K +$10.6K +2,600 +3%
GCP
13
GSA Capital Partners
United Kingdom
$256K +$905 +221 +0.3%
Corient Private Wealth
14
Corient Private Wealth
Florida
$233K +$153K +37,400 +100%
Qube Research & Technologies (QRT)
15
Qube Research & Technologies (QRT)
United Kingdom
$186K +$244K +59,519 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$182K
Northern Trust
17
Northern Trust
Illinois
$174K -$4.88K -1,192 -2%
Renaissance Technologies
18
Renaissance Technologies
New York
$168K +$45.5K +11,109 +26%
VF
19
Virtu Financial
New York
$161K +$212K +51,759 New
CA
20
CoreCap Advisors
Michigan
$150K +$5.11K +1,248 +3%
Morgan Stanley
21
Morgan Stanley
New York
$146K +$144K +35,191 +302%
WIM
22
Westside Investment Management
California
$137K +$36.9K +9,000 +26%
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$136K +$96.3K +23,526 +113%
HighTower Advisors
24
HighTower Advisors
Illinois
$128K
Marshall Wace
25
Marshall Wace
United Kingdom
$127K -$90.7K -22,159 -35%

ANIX Hedge Fund Activity: Q4 2025 in Review

71 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2025, worth a combined $17.8M — down 0.63% from $17.9M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ANIX positions and 8 closed out — a net gain of 5 holders — while 19 added to existing stakes and 13 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $703K. The largest seller was Bank of America, cutting an estimated $853K.

  • 71 institutional investors held Anixa Biosciences (ANIX) as of Q4 2025, up from 66 in Q3 2025.
  • Funds reported $17.8M of Anixa Biosciences stock for Q4 2025, down 0.63% quarter-over-quarter.
  • 13 funds opened new Anixa Biosciences positions in Q4 2025 and 8 closed out, a net change of +5 holders.
  • The largest Anixa Biosciences buyer in Q4 2025 was Susquehanna International Group, an estimated $703K added.
  • The largest Anixa Biosciences seller in Q4 2025 was Bank of America, an estimated $853K sold.

Based on aggregated 13F filings for Q4 2025.